Endpoint surrogacy in oncology Phase 3 randomised controlled trials

Jianrong Zhang, Meagan R. Pilar, Xiaofei Wang, Jingxia Liu, Herbert Pang, Ross C. Brownson, Graham A. Colditz, Wenhua Liang, Jianxing He

Research output: Contribution to journalEditorial

Abstract

Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint—instead of overall survival—would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs.

Original languageEnglish
Pages (from-to)333-334
Number of pages2
JournalBritish Journal of Cancer
Volume123
Issue number3
DOIs
StatePublished - Aug 4 2020

Fingerprint Dive into the research topics of 'Endpoint surrogacy in oncology Phase 3 randomised controlled trials'. Together they form a unique fingerprint.

Cite this